Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego.

Arcutis tacks on atopic dermatitis approval for Zoryve cream

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 10, 2024

Verve Therapeutics gets grant for gene editing compositions to lower ldl cholesterol levels

Discover how Verve Therapeutics’ new patent for gene editing targeting the PCSK9 gene could revolutionize LDL cholesterol treatment and combat cardiovascular disease.

August 24, 2024

Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase

September 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.